| Breast Cancer |
1 |
1 |
| Breast Cancer in Male |
0 |
0.99 |
| Advanced and Metastatic Breast Cancer |
0 |
0.8 |
| Triple Negative Breast Cancer |
0 |
0.79 |
| Breast |
0 |
0.67 |
| Cancer |
0 |
0.67 |
| Ovarian Cancer |
0 |
0.56 |
| Biologic Therapy |
0 |
0.55 |
| Genomic Medicine |
0 |
0.98 |
| Head and Neck Cancer |
0 |
0.54 |
| Metastasis |
0 |
0.49 |
| Targeted Cancer Therapy |
0 |
0.49 |
| Cancer Survivor |
0 |
0.48 |
| Breast Surgery |
0 |
0.43 |
| Selective Estrogen Receptor Modulators |
0 |
0.15 |
| Chemotherapy |
0 |
0.1 |
| Endocrine Therapy |
0 |
0.1 |
| Tumor |
0 |
0.1 |
| Aromatase Inhibitors |
0 |
0.08 |
| Brain Tumor |
0 |
0.07 |
| Face |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Clinical Research |
0 |
0.06 |
| Genetics |
0 |
0.06 |
| Gonadotropin-Releasing Hormone (GnRH) Agonists |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.06 |
| Scar |
0 |
0.06 |
| Surgery |
0 |
0.06 |